Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty

Bio2RDF uri

Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty

http://bio2rdf.org/clinicaltrials:NCT00564850

Bio2RDF identifier

NCT00564850

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00564850

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00564850

acronym [clinicaltrials_vocabulary:acronym]

DECAPUB

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of the stud ...... on with triptorelin 11.25 mg.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00564850 [clinicaltrials_resource:9cdc27e00984a374a7fa2775f4cf675a]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L 3 months after the first injection of triptorelin pamoate 11.25 mg [clinicaltrials_resource:0412e4fdbcdb5fc344ca2cb60a7ace39]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L 3 months after the first injection of triptorelin pamoate 11.25 mg [clinicaltrials_resource:001b7be7c08c51a9166d72040790ef6c]

Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L 3 months after the first injection of triptorelin pamoate 11.25 mg [clinicaltrials_resource:2f8f058ca7d5c36fe0eb0af4cd114bcf]

Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L 3 months after the first injection of triptorelin pamoate 11.25 mg [clinicaltrials_resource:3f818ecc59b888cf70675ae0ec9715b6]

Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L 3 months after the first injection of triptorelin pamoate 11.25 mg [clinicaltrials_resource:4170794a81a8da647ff56904385abbdf]

Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L 3 months after the first injection of triptorelin pamoate 11.25 mg [clinicaltrials_resource:4b135660a878a63cd00eb6886ad1fc6d]

Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L 3 months after the first injection of triptorelin pamoate 11.25 mg [clinicaltrials_resource:60068641fe6ee83eab71a67c78a0e6ec]

Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L 3 months after the first injection of triptorelin pamoate 11.25 mg [clinicaltrials_resource:7c1c61bb6aec831b17f0707f95fb64ec]

Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L 3 months after the first injection of triptorelin pamoate 11.25 mg [clinicaltrials_resource:880639d10258c4107a4b7785ff107eb4]

Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L 3 months after the first injection of triptorelin pamoate 11.25 mg [clinicaltrials_resource:8c9f9cd9d744e3ea2becc26dc1a802ad]

Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L 3 months after the first injection of triptorelin pamoate 11.25 mg [clinicaltrials_resource:97cd48c0b833fd8c5347974e51f33101]

completion date [clinicaltrials_vocabulary:completion-date]

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Precocious Puberty [clinicaltrials_resource:0924e1ce662d9c570dd3ea9f1dac7cba]

condition browse [clinicaltrials_vocabulary:condition-browse]

Puberty, Precocious [clinicaltrials_resource:019a31f3ff42962eaed1a7981a5d1eb6]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Puberty, Precocious [clinicaltrials_resource:019a31f3ff42962eaed1a7981a5d1eb6]

country [clinicaltrials_vocabulary:country]

France [clinicaltrials_resource:0309a6c666a7a803fdb9db95de71cf01]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00564850 [clinicaltrials_resource:c37c48898deef4a731ba20924b0d71f0]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2007-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Triptorelin pamoate 11.25mg (Decapeptyl® SR) [clinicaltrials_resource:0e57d49846d1a685cf4a436c7fc38862]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Triptorelin Pamoate [clinicaltrials_resource:6e316a4db067b268d37a683b7bc3220e]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2012-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]

location [clinicaltrials_vocabulary:location]

Hôpital Hotel-Dieu (CHU) [clinicaltrials_resource:64aa8866efc5fbbe63e6d182b2f15098]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00564850

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Phase III, Multicentre, Non-co ...... ildren With Precocious Puberty

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

2-54-52014-143

http://www.w3.org/2001/XMLSchema#string

outcome [clinicaltrials_vocabulary:outcome]

Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L [clinicaltrials_resource:NCT00564850/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

Joelle Blumberg, MD [clinicaltrials_resource:e76aeb0af0411faa1721d4e8dfe9507f]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) [clinicaltrials_resource:be0f4cc39ce377ef03a505ef7fd7a9e1]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00564850 [clinicaltrials_resource:a52704fe3eb76f85ea2de2e246e9af07]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00564850 [clinicaltrials_resource:7063cc5ed3414d306be88392515ec83d]

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]

start date [clinicaltrials_vocabulary:start-date]

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00564850 study design [clinicaltrials_resource:efef88f4a557dfe8106fb22991665455]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00564850

verification date [clinicaltrials_vocabulary:verification-date]

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00564850

http://www.w3.org/2001/XMLSchema#string